Pharmacological profile of a novel series of NK1, antagonists. In vitro and in vivo potency of benzimidazolone derivatives

European Journal of Medicinal Chemistry

Volumn 32, Issue 11, 1997, Pages 843-868

  Remond G ^c   Portevin, B ^c   Bonnet, J ^c   Canet, E ^a   Regoli, D ^b   De Nanteuil, G ^c  

^a INSTITUT DE RECHERCHES SERVIER   (France)

^b UNIVERSITÉ DE SHERBROOKE   (Canada)

^c NONE

Author keywords

Antinociceptive; Benzimidazolone; Bronchoconstriction; NK1; Tachykinin

Indexed keywords

BENZIMIDAZOLE DERIVATIVE; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; NEUROKININ 2 RECEPTOR; NEUROKININ 3 RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BRONCHOSPASM; CHEMICAL MODIFICATION; DRUG POTENCY; DRUG RECEPTOR BINDING; FEMALE; GUINEA PIG; HOT PLATE TEST; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ORAL DRUG ADMINISTRATION; RABBIT; STRUCTURE ACTIVITY RELATION;

EID: 0037488464     PISSN: 02235234     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0223-5234(97)82771-7     Document Type: Article

References (26)

1. Henry JL (1987) Discussions of nomenclature for tachykinins and tachykinin receptors. In: Substance P and Neurokinins (Henry JL et al, eds) Springer, New York, XVII-XVIII
2. Duggan AW, Hendry IA, Morton CR, Hutchison WD, Zhoa ZQ (1988) Brain Res 451, 261-273
3. Henry JL (1993) Agents Actions Suppl 41, 75-87
4. Holzer P (1988) Neuroscience 24, 739-768
5. Barnes PJ, Baraniuk JN, Belvisi MG (1991) Am Rev Respir Dis 144, 1187-1198
6. Rogers DF, Belvisi MG, Aursudkij B, Evans TW, Barnes PJ (1988) Br J Pharmacol 95, 1109-1116
7. Lowe JA, McLean S (1995) Curr Pharmacol Des l, 269-278
8. Snider RM, Constantine JW, Lowe JA, Longo KP, Lebel WS, Woody HA, Drozda SE, Desai MC, Vinick FJ, Spencer RW, Hess HJ (1991) Science 251, 435-137
9. McLean S, Ganong A, Seymour PA, Snider RM, Desai MC, Rosen T, Bryce DK, Longo KP, Reynolds LS, Robinson G, Schmidt AW, Siok C, Heym J (1993) J Pharmacol Exp Ther 267, 472-479
10. Emonds-Alt X, Doutremepuich JD, Heaulme M, Neliat G, Santucci V, Steinberg R, Vilain P, Bichon D, Ducoux JP, Proietto V, Van Broeck D, Soubrie P, Le Fur G, Breliere JC (1993 ) Eur J Pharmacol 250, 403-413
11. Achard D, Grisoni S, Malleron JL, Peyronel JF, Tabart M (1993) World Patent 93/21155
12. McLeod AM, Cascieri MA, Merchant KJ, Sadowski S, Hardwicke S, Lewis RT, McIntyre DE, Metzger JM, Fong TM, Shepheard S, Tattersall FD, Hargreaves R, Baker R ( 1995) J Med Chem 38, 934-941
13. Hipskind PA, Howbert JJ, Bruns RF, Cho SSY, Crowell TA, Foreman MM, Gehlert DR, lyengar S, Johnson KW, Krushinski JH, Li DL, Lobb KL, Mason NR, Muehl BS, Nixon JA, Phebus LA, Regoli D, Simmons RM, Threlkeld PG, Waters DC, Gitter BD (1996) J Med Chem 39, 736-748
14. Laben G, Gunther W, Kazmirowski HG, Menzer M, Czernotsky K, Muller R, Moller G (1990) DDR Patent 272 841
15. Israel M, Jones LC, Joullié M (1971 ) J Het Chem 8, 1015-1018
16. Gomez-Parra V, Jimenez M (1989) Liebigs Ann Chem, 539-544
17. Nantel F, Rouissi N, Rhaleb N, Jukic D, Regoli D (1991) J Cardiovasc Pharmacol 18, 398-405
18. Regoli D, Drapeau G, Dion S, Couture R (1988) Trends Pharmacol Sci 9, 290-295
19. Bagley JR, Lalinde NL, Huang BS, Spencer HK (1990) European Patent 396 282 A2
20. Ogura H, Takayanagi H, Yamazaki Y, Yonesawa S, Takagi H, Kobayashi S, Kamioka T, Kamoshita K (1972) J Med Chem 15, 923-926
21. For the selectivity studies, compound 13 was evaluated on the following receptors: α1, α2, 5HT1A, 5HT1B, 5HT2, 5HT3, D1, D2, A1, H1, Ach-M, μ, BZC, Cannabinoid.
22. Eddy NB, Leimbach D (1953) J Pharmacol Exp Ther 107, 385-393
23. Eum SY, Hailé S, Lefort J, Huerre M, Vargaftig BB (1995) Proc Natl Acad Sci USA 92, 12290-12294
24. Payan DG, McGillis JP, Organist ML (1986) J Biol Chem 261, 14321-14329
25. Takeda Y, Blount P, Herschey AD, Raddatz R, Sachais BS, Krause JE (1992) J Neurochem 59, 740-745
26. Goldstein A, Naidu A (1989) Mol Pharmacol 36, 265-272